An Extension of Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Pegylated Interferon and Ribavirin After Completing Treatment in a Phase 2 Study and Have Relapsed After at Least 44 Weeks Tx With Peg-IFN and RBV.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Golotimod (Primary) ; Ribavirin
Indications Hepatitis C
Focus Adverse reactions; Therapeutic Use
Sponsors SciClone Pharmaceuticals

Most Recent Events

07 Mar 2012 Actual patient number is (12) as reported by ClinicalTrials.gov (Extension trial; NCT01310205).
07 Mar 2012 Actual end date is (1 Mar 2012) as reported by ClinicalTrials.gov (Extension trial; NCT01310205).
07 Mar 2012 Actual initiaion date is (1 Aug 2010) as reported by ClinicalTrials.gov (Extension trial; NCT01310205).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight